Compared with cutaneous leishmaniasis, vaccination against visceral leishmaniasis has received limited attention. Most available drugs are toxic, and relapse after cure remains a chronic problem. Growing limitations in available chemotherapeutic strategies due to emerging resistant strains and lack of an effective vaccine strategy against visceral leishmaniasis deepens the crisis. Complete soluble antigen (CSA), from a b1-4 galactosyltransferase expressing attenuated Leishmania donovani parasite, induced protection against subsequent challenge and during active infections. CSA immunization was effective against both pentavalent antimony sensitive and resistant strains of L. donovani. Majority ($85%) of the immunized animals showed sterile protection. Resolution of the disease required the presence of T cells, and the recovered animals remained immune to re-challenge. Control of the parasites was dependent on type 1 CD4 1 helper cells, which evolved in the presence of IL-12 and activated macrophages through the production of IFN-c. Immunity was adoptively transferable and was dependent on both CD4 1 and CD8 1 cells. CSA immunization led to enhanced IFN-c production, while suppressing the IL-10 production. However, CSA immunization did not abrogate IL-4 production. Our results accentuate the need to establish a favorable cellular immunity while intervening with the development of Th2 cells during leishmania infection.Key words: Cytokines . Immunoprophylaxis . Immunotherapy . Parasitic-protozoan . Th1/Th2Supporting Information available online
IntroductionProtozoan parasites in the genus leishmania are responsible for a spectrum of human diseases termed Leishmaniasis. Visceral leishmaniasis (VL), or kala-azar, caused by Leishmania donovani (LD), is the most fatal form of leishmaniasis, afflicting millions of people worldwide [1]. No vaccination is available against leishmaniasis, and the fast spreading drug resistance in these parasitic organisms emphasizes the need for a safe, effective vaccine [2].Several vaccination strategies against experimental leishmaniasis have been attempted. However, a successful vaccine against the disease has been elusive. Protective immunity in human and experimental leishmaniasis is predominantly of the Th1 type. This makes immunogens with Th1 stimulatory potential good vaccine candidates. Absence of type 1 immune response to leishmania antigens has been documented in VL patients. A number of candidate antigens, including GP63 (the 63 kDa major surface protease), p36/LACK (leishmania homology of receptors for activated C-kinase), KMP-11 (kinetoplastid membrane protein-11), HASPB (hydrophilic acetylated surface protein), A2 (amastigote stage specific gene family, termed ''A2''), CPB (cysteine proteinase type 11) or other integral membrane proteins of leishmania parasites have been used with partial success
2146for vaccination against Leishmania challenge [3,4]. However, strong Th1-inducing adjuvants have usually been required, including IL-12, CpG-containing DNA constructs or delivery...